Hadasit Bio-Holdings to Participate in Hadassah Centennial Convention

JERUSALEM, Oct. 16, 2012 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (OTC: HADSY, TASE: HDST) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that Ophir Shahaf, the Company's Chief Executive Officer, will be a member of the Hadassah Centennial Convention's Business Session panel on Thursday, October 18th in Jerusalem.

As part of the panel, Mr. Shahaf will lead discussions and field questions from over 400 Hadassah Associates.  Topics covered will range from the innovative model used by Hadasit Bio-Holdings to commercialize and finance biotechnology innovation stemming from a leading research center, to recent developments in some of the promising companies that comprise the Hadasit Bio-Holdings portfolio, to current trends in the biotechnology industry, and much more.  Mr. Shahaf's extensive experience in the biotech industry and as the CEO of Hadasit Bio-Holdings for over five years will provide invaluable insight for those in attendance.

The Company is also pleased to announce that its stock now has Blue Sky exemption in over 30 states.  Obtaining Blue Sky exemption allows financial advisors and brokers to solicit the stock to their clients. 

"I am very excited to have the opportunity to speak with so many interested parties at the Centennial Convention.  This will be a great event where people can learn a lot about Hadasit Bio-Holdings and the amazing science we are producing," stated Mr. Shahaf.  "Additionally, now that we are Blue Skied in various states across the U.S., it will allow for increased visibility and liquidity in the trading of our ADR, and enable a wider audience to participate in these highly promising companies, all 'born and bred' within Hadassah - a leader in medical and scientific innovation."

About Hadasit Bio-Holdings

Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center. The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. Its portfolio companies develop drugs with blockbuster potential (with markets worth over one billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.

For more information please visit: www.hbl.co.il

Investor Contact:
KCSA Strategic Communications
Phil Carlson / Josh Dver
212.896.1233 / 1239
[email protected] / [email protected]

SOURCE Hadasit Bio-Holdings Ltd.